Home › Breast Cancer › Texas › Austin
Breast Cancer clinical trials in Austin, TX
15 studies for Breast Cancer are looking for participants at sites in and around Austin (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
RecruitingPhase 1
- Next Oncology Austin, Austin
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RecruitingPhase 3
- Texas Oncology Central/South, Austin
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecruitingPhase 1/2
- Texas Oncology - Central / South Texas, Austin
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
RecruitingPhase 2
- Texas Oncology - Central South, Austin
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
RecruitingPhase 1
- NEXT Austin, Austin
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
RecruitingPhase 1/2
- Texas Oncology, Austin
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RecruitingPhase 3
- Texas Oncology - Central/South Texas, Austin
- Texas Oncology - Central South (Balcones Dr), Austin
- Texas Oncology - Central South (James Casey), Austin
- and 1 more
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- New Experimental Therapeutics - NEXT Oncology, Austin
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RecruitingPhase 1
- NEXT Oncology - Austin, Austin
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RecruitingPhase 2/3
- Texas Oncology - Central/South Texas, Austin
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
RecruitingPhase 3
- Texas Oncology - Austin, Austin
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
RecruitingPhase 1/2
- Texas Oncology - Central/South, Austin
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
- NEXT Oncology Austin, Austin
Sample Collection for Ongoing Research and Product Evaluation Study
RecruitingObservational study
- Natera, Inc., Austin
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
RecruitingObservational study
- Texas Oncology - Austin, Austin
About Breast Cancer
Breast cancer is a cancer that starts in the breast tissue, when cells change and grow out of control. Learn about the types, diagnosis, and treatments.
More about Breast Cancer on MedlinePlus
Breast Cancer trials in other cities
- New York City, NY144 studies
- Houston, TX126 studies
- Boston, MA110 studies
- Nashville, TN78 studies
- Los Angeles, CA73 studies
- Edison, NJ70 studies
- Queens, NY67 studies
- Durham, NC63 studies
- St. Louis, MO63 studies
- Chicago, IL59 studies
- Dallas, TX54 studies
- Philadelphia, PA51 studies
Other studies in Austin
- Non-Small Cell Lung Cancer29 studies
- Cancer (all types)22 studies
- Obesity22 studies
- Overweight19 studies
- Metastatic Cancer18 studies
- Colorectal Cancer17 studies
- Ovarian Cancer17 studies
- Heart Failure17 studies
- Endometrial Cancer15 studies
- Type 2 Diabetes14 studies
- Prostate Cancer14 studies
- Steatotic Liver Disease13 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.